In conclusion, our results demonstrate that FPR2 mediates sex-specific responses to diet-induced NAFLD/NASH, suggesting a novel therapeutic target for NAFLD/NASH. Here, FPR2 is linked to metabolic dysfunction-associated steatohepatitis.